FIELD: biochemistry.
SUBSTANCE: invention relates to an antibody or antigen-binding fragment thereof, capable of specifically binding to Sortilin and to inhibit or reduce binding of progranulin with Sortilin, as well as to a pharmaceutical composition containing said composition. Also disclosed is use of said antibody or antigen-binding fragment thereof when preparing a medicament for treating a disease, associated with decreased levels of progranulin in the patient's brain.
EFFECT: invention enables effective prevention or treatment of a disease associated with low progranulin levels in a patient's brain.
19 cl, 18 dwg, 6 tbl, 17 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BINDING MOLECULES, BINDING PD-L1 AND LAG-3 | 2017 |
|
RU2784388C2 |
| LIGAND-BINDING MOLECULE WITH REGULATED LIGAND-BINDING ACTIVITY | 2017 |
|
RU2803067C2 |
| CD131-BINDING PROTEINS AND THEIR APPLICATIONS | 2016 |
|
RU2773927C2 |
| HUMAN ANTIBODIES BINDING TO ROR2 | 2018 |
|
RU2784586C2 |
| CD47-ANTIGEN-BINDING UNIT AND ITS USE | 2018 |
|
RU2780859C2 |
| POLYVALENT AND POLYSPECIFIC GITR-BINDING FUSED PROTEINS | 2016 |
|
RU2753439C2 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| PROTEINS BINDING NKG2D, CD16 AND TUMOUR-ASSOCIATED ANTIGEN | 2018 |
|
RU2816716C2 |
| POLYVALENT AND POLYSPECIFIC OX40-BINDING FUSED PROTEINS | 2017 |
|
RU2773052C2 |
| ANTI-PCSK9 ANTIBODY, ITS ANTIGEN-BINDING DOMAIN AND MEDICAL APPLICATION THEREOF | 2016 |
|
RU2739208C2 |
